| 產(chǎn)品名稱 |
Ab 23.1 |
| 商品貨號 |
B163900 |
| Organism |
Mus musculus (B cell); Mus musculus (myeloma), mouse (B cell); mouse (myeloma) |
| Cell Type |
hybridoma: B lymphocyte |
| Product Format |
frozen |
| Morphology |
lymphoblast |
| Culture Properties |
suspension |
| Biosafety Level |
1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease |
Carcinoma |
| Applications |
Animals were immunized with membrane preparations of NIH3T3 cells engineered to overproduce erbB protein. The antibody reacts with the extracellular domain of gp185erbB-2. |
| Disclosure |
This material is cited in a US or other Patent and may not be used to
infringe the claims. Depending on the wishes of the Depositor, ATCC may be
required to inform the Patent Depositor of the party to which the material was
furnished. This material may not have been produced or characterized by ATCC. |
| Derivation |
Spleen cells were fused with P3X8g8.653 myeloma cells. |
| Genes Expressed |
immunoglobulin; monoclonal antibody; against human erbB-2 protein |
| Cellular Products |
immunoglobulin; monoclonal antibody; against human erbB-2 protein |
| Tumorigenic |
Yes |
| Effects |
Yes, forms ascites in pristane primed BALB/c mice |
| Comments |
Animals were immunized with membrane preparations of NIH3T3 cells engineered to overproduce erbB protein. Spleen cells were fused with P3X8g8.653 myeloma cells. The antibody reacts with the extracellular domain of gp185erbB-2. In vitro and in vivo the antibody has no effect upon N87 cells (an erbB overexpressing human gastric carcinoma). However, in combination with Ab 21.1 (see ATCC HB-11601) in vitro growth of N87 is suppressed and in vivo N87 xenografts can prevented or be caused to regress by a combination of the two antibodies. The antibodies induce autophosphoryaltion of the gp185erbB-2 protein. |
| Complete Growth Medium |
Depositor's culture medium: Dulbecco's modified Eagle's medium, 10% NCTC 109,
15% fetal bovine serum, 1% hybridoma cloning media. |
| Subculturing |
Medium Renewal: Every 2 to 3 days Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 2 X 10 exp5 cells/ml and maintain between 1 X 10 exp5 and 1 X 10 exp6 cells/ml. |
| Isotype |
IgG1 |
| Name of Depositor |
Aronex Pharmaceuticals Inc. |
| U.S. Patent Number |
|
| References |
King CR, et al. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof. US Patent 5,587,458 dated Dec 24 1996
|
